Amgen Inc. $AMGN Stock Position Lowered by Trilogy Capital Inc.

Trilogy Capital Inc. decreased its stake in Amgen Inc. (NASDAQ:AMGN) by 2.6% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,717 shares of the medical research company’s stock after selling 285 shares during the quarter. Trilogy Capital Inc.’s holdings in Amgen were worth $2,992,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in AMGN. Brighton Jones LLC lifted its position in Amgen by 23.5% in the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after buying an additional 5,226 shares in the last quarter. NBC Securities Inc. raised its holdings in Amgen by 111,133.3% in the 1st quarter. NBC Securities Inc. now owns 6,674 shares of the medical research company’s stock worth $2,079,000 after acquiring an additional 6,668 shares during the period. Vantage Wealth grew its position in Amgen by 4.2% in the 1st quarter. Vantage Wealth now owns 69,614 shares of the medical research company’s stock worth $21,688,000 after purchasing an additional 2,813 shares during the last quarter. Merit Financial Group LLC grew its position in Amgen by 8.6% in the 1st quarter. Merit Financial Group LLC now owns 20,252 shares of the medical research company’s stock worth $6,309,000 after purchasing an additional 1,609 shares during the last quarter. Finally, HBW Advisory Services LLC grew its position in Amgen by 10.8% in the 1st quarter. HBW Advisory Services LLC now owns 9,484 shares of the medical research company’s stock worth $2,955,000 after purchasing an additional 925 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

Shares of AMGN stock opened at $282.20 on Wednesday. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $335.88. The firm’s 50 day moving average is $287.95 and its 200-day moving average is $288.57. The firm has a market capitalization of $151.93 billion, a price-to-earnings ratio of 23.07, a PEG ratio of 2.38 and a beta of 0.49. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 7.24.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.28 by $0.74. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The company had revenue of $9.18 billion for the quarter, compared to analyst estimates of $8.86 billion. During the same period in the prior year, the business earned $4.97 earnings per share. Amgen’s quarterly revenue was up 9.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. Sell-side analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, September 12th. Investors of record on Friday, August 22nd were paid a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.4%. The ex-dividend date of this dividend was Friday, August 22nd. Amgen’s payout ratio is 77.84%.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on AMGN shares. Wall Street Zen lowered shares of Amgen from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Cantor Fitzgerald reiterated a “neutral” rating and set a $305.00 target price on shares of Amgen in a research report on Tuesday, June 24th. Bank of America lifted their target price on shares of Amgen from $261.00 to $272.00 and gave the company an “underperform” rating in a research report on Friday, September 26th. William Blair reiterated an “outperform” rating on shares of Amgen in a research report on Tuesday, June 24th. Finally, Citigroup boosted their price target on shares of Amgen from $310.00 to $315.00 and gave the company a “neutral” rating in a research report on Wednesday, September 24th. Seven research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $309.70.

Insider Buying and Selling at Amgen

In related news, SVP Nancy A. Grygiel sold 1,267 shares of the business’s stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total transaction of $376,286.33. Following the completion of the sale, the senior vice president directly owned 7,209 shares of the company’s stock, valued at $2,141,000.91. The trade was a 14.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.69% of the stock is currently owned by company insiders.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.